May 2, 2019 10:40 AM EDTUpdated 01:39 PM
Financing
R&D

Weeks af­ter a Pfiz­er/Mer­ck KGaA break­down, Clo­vis gam­bles on a $175M loan to fin­ish a glob­al PhI­II PARP/PD-1 com­bo study

John Carroll

Editor & Founder

Clo­vis On­col­o­gy CEO Patrick Ma­haffy $CLVS has en­gi­neered a risky gam­ble to pay for his big Phase III study com­bin­ing his PARP Rubra­ca with Bris­tol …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

Neu­ro­gene's stock falls in post-mar­ket trad­ing af­ter ear­ly da­ta in Rett syn­drome

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times